Biologics/Immunotherapy News

Hazelnut oral immunotherapy was safe and effective, but cross-desensitization for patients who also had walnut and cashew allergy was unlikely, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

In February, the FDA approved the Odactra tablet, a sublingual immunotherapy, to treat house dust mite-induced allergic rhinitis in patients aged 5 to 11 years, according to a manufacturer-issued press release.

SAN DIEGO — Patients with higher eosinophil counts experienced more cardiovascular disease, according to a poster presented at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization Joint Congress.

Patients with small airways dysfunction experienced clinically and statistically significant improvements in peripheral resistance and compliance with tezepelumab, according to a study published in Annals of Allergy, Asthma & Immunology.

SAN DIEGO — Patients with hereditary angioedema who switched from other drugs to donidalorsen for long-term prophylaxis experienced fewer attacks and improved disease control, according to a poster presented here.

SAN DIEGO — Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and 2023, according to a poster presented here.

SAN DIEGO — Patients with severe asthma required fewer steroid bursts with tezepelumab-ekko, according to a poster presented at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization Joint Congress.

SAN DIEGO — Approximately 45,000 patients have begun using omalizumab for food allergy in the year since its approval by the FDA, Ahmar Iqbal, MD, therapeutic area lead for respiratory and influenza at Genentech, told Healio here.

SAN DIEGO — Odds for desensitization and remission fell as patients missed consecutive doses of peanut oral immunotherapy, according to a poster presented here.